Amanda Dannenbring, DO
Family Medicine · Dakota Dunes, SDNPI 1063677110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $919, 3.3 times the $281 reported in 2019. Among family medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$945
- Amgen$567
- Astellas Pharma US Inc$520
- Novo Nordisk$408
- Pfizer$342
- GSK$122
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,79793%
- Education$3007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $945 |
| Amgen | 41 | $567 |
| Astellas Pharma US Inc | 18 | $520 |
| Novo Nordisk | 29 | $408 |
| Pfizer | 25 | $342 |
| GSK | 9 | $122 |
| Merck | 6 | $96 |
| E.r. Squibb & Sons, L.L.C. | 7 | $92 |
| Johnson & Johnson | 5 | $77 |
| AstraZeneca | 5 | $73 |
| Medtronic | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Lilly USA, LLC | 5 | $62 |
| Bayer | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Amarin Pharma, Inc. | 4 | $56 |
| Novartis | 3 | $39 |
| Grifols USA, LLC | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Biogen | 2 | $31 |
| VBI Vaccine (delaware) Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Nalpropion Pharmaceuticals LLC | 2 | $24 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| CSL Behring | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$4,097 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $107,956 |
| MounjaroTirzepatide | 47 | $61,164 |
| JardianceEmpagliflozin | 59 | $58,172 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $43,810 |
| EliquisApixaban | 35 | $37,724 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $27,549 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $27,411 |
| JanuviaSitagliptin Phosphate | 25 | $24,521 |
| RexultiBrexpiprazole | 13 | $17,758 |
| TradjentaLinagliptin | 16 | $17,571 |
| MyrbetriqMirabegron | 18 | $16,511 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,074 |
| Repatha SureclickEvolocumab | 12 | $6,627 |
| SynthroidLevothyroxine Sodium | 56 | $5,162 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $408 | $107,956114 claims |
| Boehringer IngelheimJardiance, Tradjenta | $35 | $75,74375 claims |
| Lilly USA, LLCMounjaro | $62 | $61,16447 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $122 | $50,82678 claims |
| PfizerEliquis | $342 | $37,72435 claims |
| MerckJanuvia | $96 | $24,52125 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $64 | $17,75813 claims |
| Astellas Pharma US IncMyrbetriq | $520 | $16,51118 claims |
| AbbVieSynthroid | $945 | $5,16256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Dakota Dunes
- Nancy SchenkDakota Dunes$3K
- Lisa Remer-GilletteDakota Dunes$2K
- Brianna BrownleeDakota Dunes$1K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Terry GraberCuster$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.